FDA Activities

  • Commissioner Gottlieb’s pharma regulations in the year ahead
  • FDA’s planned homeopathic regulations
  • First drug approved through FDS’s new 505 (b)(2) process
  • First gene therapy for rare blindness condition approved

Comments are closed.